title: Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia.
abstract: Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.
authors.affiliation: Hematology Service, Hospital Santa Marcelina, São Paulo, SP, Brazil.
authors.forename: Monika
authors.initials: M
authors.lastname: Conchon
authors.forename: Carla Maria Boquimpani de Moura
authors.initials: CM
authors.lastname: Freitas
authors.forename: Maria Aparecida do Carmo
authors.initials: MA
authors.lastname: Rego
authors.forename: José Wilson Ramos
authors.initials: JW
authors.lastname: Braga Junior
keywords: Clinical Trial; Drug interactions; Drug resistance, neoplasm; Drug toxicity; Gastrointestinal tract/drug effects; Interferonalpha/administration & dosage; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Piperazines/therapeutic use; Pyrimidines